Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affymax, Inc.
Affymax begins clinical trial of Hematide to treat anemia in patients with aplasia
May 8th, 2006
Affymax, Inc., a clinical-stage pharmaceutical company, announced that it has initiated a clinical trial to evaluate the use of Hematide to treat anemia in chronic kidney disease (CKD) patients with pure red cell aplasia (PRCA). PRCA, a rare autoimmune disorder, occurs when the body produces neutralizing antibodies to recombinant human erythropoietin (EPO), thus suppressing the production of red blood cells by the bone marrow. Hematide is a synthetic, peptide-based, next-generation erythropoiesis-stimulating agent (ESA) with no sequence homology to human EPO. Hematide is designed to stimulate the production of red blood cells and is being evaluated in phase II clinical...
Source: Biotech Week (2006-05-08)
|
